Antares Pharma, Inc. acquired by Halozyme Therapeutics
Halozyme Therapeutics agreed to acquire Antares Pharma, Inc., a life sciences / drug delivery technologies brand, on Apr 13, 2022.
Transaction summary
- Target
- Antares Pharma, Inc.
- Acquirer
- Halozyme Therapeutics
- Seller
- -
- Announced
- 2022-04-13
- Geography
- -
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-06-19
- Latest update
- 2026-10-21
Value and multiples
100% enterprise value
Undisclosed
Value not disclosed
Basis: FundComb estimate
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
4.9x
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Basis
- The 4.9x revenue multiple comes from FundComb’s comps spreadsheet and is not confirmed by a public source; the price, revenue and period behind it are not stated. The Wall Street Journal reported on 13 April 2022 that Halozyme Therapeutics agreed to buy Antares Pharma.
Source summary
Halozyme Therapeutics Agrees to Buy Antares Pharma - WSJ
ConfirmedContinue your research
Related transaction comps
Drug Delivery Technologies
Capsugel S.A. acquired by Lonza Group
2016-12-15 · Confirmed
View transaction → Pharma ServicesViatris OTC business acquired by Cooper Consumer Health
2023-10-01 · Confirmed
View transaction → Pharma ServicesE-Pharma Trento acquired by Wise Equity
2026-08-07 · Confirmed
View transaction → Pharma ServicesClario Holdings, Inc. acquired by Thermo Fisher Scientific
2025-10-29 · Confirmed
View transaction →